ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
← catalyst calendarNCT06816992 · readout ≤ 134 d
Sponsored by ORIC Pharmaceuticals (industry) · ORIC — their whole pipeline →. With Janssen Research and Development LLC.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
76estimated
Sites
4
Countries
Australia, Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-27 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumors
- EGFR Exon 20 Insertion Mutations
- NSCLC
- EGFR-mutated NSCLC
Interventions
- Drug: ORIC-114 Dose 1 + amivantamab
- Drug: ORIC-114 Dose 2 + amivantamab
- Drug: ORIC-114 Dose 3 + amivantamab
Primary outcomes
what the primary-completion date above is the date OFRecommended Phase 2 Dose (RP2D)
measured 12 months
Objective response rate (ORR)
measured 12 months
Duration of response (DOR)
measured 12 months
Progression-free survival (PFS)
measured 12 months
Permalink · ORIC's whole pipeline · Catalyst calendar · Every registered study · What changed